Topic

New Jersey

A collection of 504 issues

Getting Arikayce (Amikacin Liposome Inhalation) Covered by Blue Cross Blue Shield in New Jersey: Complete Guide to Prior Authorization and Appeals

Answer Box: Fast Track to Arikayce Coverage in New Jersey Arikayce (amikacin liposome inhalation) requires prior authorization from Horizon Blue Cross Blue Shield of New Jersey for refractory MAC lung disease. To get approved: (1) Submit PA request with 6+ months of failed standard MAC therapy documentation, (2) Include positive

How to Get Skyrizi (Risankizumab) Covered by Aetna CVS Health in New Jersey: Complete Guide with Forms and Appeals

Answer Box: Getting Skyrizi Covered by Aetna CVS Health in New Jersey Aetna CVS Health requires prior authorization for Skyrizi (risankizumab) with documented TNF inhibitor failure for psoriasis. Submit requests via Availity portal at least 2 weeks in advance. If denied, you have 180 days to appeal internally, then file

How to Get Venclexta (venetoclax) Covered by Cigna in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Quick Path to Venclexta Coverage Cigna requires prior authorization for Venclexta (venetoclax) through Express Scripts/Accredo specialty pharmacy for CLL, AML, and related blood cancers. Your oncologist submits via CoverMyMeds or fax with diagnosis codes, prior therapy records, and a complete tumor lysis syndrome (TLS) monitoring plan. Standard

If Ferriprox (Deferiprone) Isn't Approved by Cigna in New Jersey: Formulary Alternatives & Exception Paths

Answer Box: When Ferriprox Isn't Covered If Cigna denies Ferriprox (deferiprone) in New Jersey, you have two main paths: try formulary alternatives like deferasirox (Jadenu/Exjade) or deferoxamine, or request a formulary exception citing medical necessity. Cigna typically covers deferasirox as a preferred oral iron chelator, while deferoxamine

How to Get Takhzyro (lanadelumab-flyo) Covered by Blue Cross Blue Shield in New Jersey: Complete PA Forms and Appeals Guide

Answer Box: Getting Takhzyro Covered in New Jersey Horizon Blue Cross Blue Shield of New Jersey requires prior authorization for Takhzyro (lanadelumab-flyo) with confirmed HAE Type I/II diagnosis via C4/C1-INH labs, attack history documentation, and specialist prescription. Submit PA through provider portal with medical necessity letter; if denied,

How to Get Helixate (rFVIII) Covered by Humana in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Fast Track to Helixate Coverage Humana requires prior authorization for Helixate (recombinant factor VIII) in New Jersey. Submit via Humana's provider portal with hemophilia A diagnosis, factor VIII levels, inhibitor testing, and bleeding history. If denied, file internal appeals within 60 days, then use New Jersey&

How to Get Myozyme (alglucosidase alfa) Covered by Humana in New Jersey: Coding, Prior Authorization, and Appeals Guide

Answer Box: Getting Myozyme Covered by Humana in New Jersey Myozyme (alglucosidase alfa) requires prior authorization from Humana Medicare Advantage plans and is covered under Medicare Part B when medically necessary for confirmed Pompe disease. Use ICD-10 code E74.02, HCPCS J0171, and submit PA requests through Humana's

How to Get Opfolda (miglustat) Covered by UnitedHealthcare in New Jersey: Complete Coverage Guide and Appeals Process

Answer Box: Getting Opfolda Coverage in New Jersey UnitedHealthcare covers Opfolda (miglustat) only when prescribed with Pombiliti for late-onset Pompe disease (LOPD) in adults ≥40 kg who show inadequate response to current enzyme replacement therapy. Submit prior authorization via UnitedHealthcare Provider Portal with documented ERT failure evidence. If denied, appeal

Getting Zolgensma Covered by Cigna in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Zolgensma Covered by Cigna in New Jersey Zolgensma (onasemnogene abeparvovec-xioi) requires prior authorization from Cigna but is covered as a one-time specialty medication. For fastest approval: 1) Submit PA with genetic confirmation (≤3 SMN2 copies), anti-AAV9 titer ≤1:50, and baseline labs through CoverMyMeds or Cigna provider

Lowering Out-of-Pocket Costs for Darzalex (Daratumumab) with UnitedHealthcare in New Jersey: Copay Cards, Appeals, and Financial Assistance

Answer Box: Reducing Darzalex Costs with UnitedHealthcare in New Jersey Darzalex (daratumumab) costs with UnitedHealthcare can be reduced through Janssen CarePath copay assistance ($5-10 per infusion, $15,000 annual cap for commercial plans), tier exception requests for high specialty tiers, and New Jersey's external appeal process via IHCAP.